MRI contrast agents, especially gadolinium-based ones, can improve diagnostic accuracy but also carry potential health risks. Updated clinical recommendations emphasize careful patient selection, dose ...

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best NASDAQ stocks with the highest upside potential.

BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...

A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between ...

A review of cases using MRI with and without contrast agent found perfect or near-perfect agreement in most cases when evaluating patients with short stature for growth hormone deficiency. Gadolinium ...

GE HealthCare Technologies Inc. GEHC recently announced that the first patient has been dosed in its Phase 2/3 LUMINA ...

CORVALLIS, Ore. (KTVZ) -– Scientists at Oregon State University have filed a patent on a design for a new magnetic resonance imaging contrast agent with the potential to outperform current agents ...

Adding a contrast-enhancing agent to magnetic resonance imaging (MRI) significantly improves image quality and allows radiologists who interpret MRI scans to pick up subtle anatomic details and ...

Heart attack and stroke are the first and second leading causes of death in developed countries, respectively. As the disease often results in sudden death with few special prognostic symptoms, early ...

A new compound has been invented to bind to liver cells that are in the early stages of damage, thus making it easier to pick them up using MRI (magnetic resonance imaging). As reported in the journal ...

Simulations reveal details about the magnetic interactions between gadolinium contrast agents used in MRI scans and their environment. You can keep your best guesses. Engineers at Rice University's ...

GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 ...